BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:ChemBio e-seminar by Prof. Georg Winter
DTSTART:20221018T161500
DTEND:20221018T171500
DTSTAMP:20260508T024516Z
UID:4b5c9d9da25ae1c4a6c7144df4180eb6c847f3edb5ab499d054bac41
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Georg Winter\n\nCeMM Research Center for Molecular Medic
 ine of the Austrian Academy of Sciences\nTitle: Disrupting Gene Control vi
 a Targeted Protein Degradation\n\nAbstract:\nThematically\, we are working
  at the interface of chemical biology\, cancer and gene control. We aim to
  innovate novel pharmacologic strategies that allow us to probe\, understa
 nd and eventually disrupt aberrant transcriptional circuits in cancer. Our
  science is thus unapologetically translational\, but we nevertheless aim 
 to ask scientific questions that are fundamental in nature\, allowing us t
 o develop a better understanding of transcription regulation and the ubiqu
 itin-proteasome system.\nOur research strategy is inspired and driven by h
 igh-throughput and unbiased technologies such as quantitative proteomics\,
  (nascent) transcriptomics and particularly functional genomics. Connectin
 g these technologies with synthetic chemistry enables us to understand the
  mechanism of action of proteins\, protein complexes or small molecules bo
 th on a holistic but also mechanistic level.\nCurrently\, the main focus o
 f the group is to explore the concept of proximity-inducing small molecule
 s that enable us to rewire cellular circuits by acting as „chemical neom
 orphs“. This includes\, but also transcends to concept of targeted prote
 in degradation via molecular glues and PROTACs.\n\nSpeaker's biography:\nG
 eorg Winter\, PhD\, obtained his degree from the Medical University of Vie
 nna\, working on elucidating the mechanism of action of anti-neoplastic dr
 ugs. He specialized on proteomics- as well as chemical genetics approaches
  to identify drug resistance mechanisms and synergistic drug combinations.
  He continued his training in chemical biology\, working as a postdoctoral
  fellow with Dr. James Bradner the Dana Farber Cancer Institute/Harvard Me
 dical School. Supported by an EMBO fellowship\, he published the first pap
 er reporting on in vivo target protein degradation (Winter et al.\, Scienc
 e 2015). His postdoctoral work led to the foundation of C4 Therapeutics\, 
 now listed at the NASDAQ. He was recruited as a CeMM Principal Investigato
 r in June 2016 where his research is focused on using the unique pharmacol
 ogy of targeted protein degradation to understand and disrupt aberrant gen
 e control circuits in cancer His interdisciplinary research lab consists o
 f 7 Postdocs\, 5 graduate students and 5 technical assistants trained in m
 olecular biology\, organic chemistry and computational biology\, and is su
 pported by several national and international grants and fellowships inclu
 ding an ERC Starting Grant. Moreover\, Dr. Winter is a coordinator of a re
 search partnership between CeMM and Pfizer. His work on molecular glue deg
 raders led to the incorporation of Proxyen in May 2020. His work on PROTAC
 s contributed to the incorporation of Solgate Therapeutics. Dr. Winter’s
  contribution to the field of targeted protein degradation was acknowledge
 d via multiple prices and awards\, including the Wilson S. Stone Memorial 
 Award from MD Anderson (2021)\, the Eppendorf Award 2019 the Elisabeth Lut
 z Award of the Austrian Academy of Sciences.\n\nLab website: https://www.w
 inter-lab.com/
LOCATION:https://epfl.zoom.us/j/64385868188
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR